Clinical trials: ALS
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
CAPTURE ALS is a long-term data and biorepository platform that will facilitate future ALS research. CAPTURE ALS will provide the standardized systems and tools necessary to collect, store, and analyze vast amounts of multimodal…
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Degeneration
- Trial name
- CAPTURE ALS (NCT05204017)
- Where
- 4 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Amyotrophic Lateral Sclerosis
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
The study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal derived neural stem cell transplantation for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01730716
- Testing
- Human spinal cord stem cell implantation
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neuralstem Inc.
Amyotrophic Lateral Sclerosis, Motor Neurone Disease
Measurement and Impact of Physical Impairment in Amyotrophic Lateral Sclerosis: Use of Digital Technologies - A Precision ALS Project
Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neuron Disease (MND), is a neurodegenerative disease. At present there are limited treatment options for this disease which progressively affects physical…
- Trial name
- TechnicALS (NCT06820008)
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University of Dublin, Trinity College
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset).
- Trial name
- ASTRALS (NCT06643481)
- Testing
- VHB937
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Brain Injury, Cerebral Palsy
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders
This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for patients with brain injury or…
- Conditions
- Brain Injury, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Parkinson's Disease
- Trial name
- NCT02236065
- Testing
- Umbilical cord blood therapy, Filgrastim
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- MinYoung Kim, M.D.
Amyotrophic Lateral Sclerosis
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
This research is being done to see if the ketogenic diet (which is high in fat and low in carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are fed through a gastrostomy tube.
- Trial name
- NCT01016522
- Testing
- KetoCal
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis (ALS)
DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
This study is intended to obtain clinical information and establish a repository of DNA, RNA, peripheral blood monocyte, lymphocyte and skin tissue samples from people with ALS and related neurodegenerative motor neuron diseases…
- Trial name
- NCT01699451
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis: a New Paradigm
Amyotrophic Lateral Sclerosis (ALS) is a degenerative neuromuscular disease, progressing inexorably to respiratory failure, the by involvement of respiratory muscles, the commitment with most impact on the prognosis of ALS.
- Trial name
- ALSParadigm (NCT03073239)
- Testing
- ALS patients genetic characterization, ALS patients epidemiological caracterization
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Conde, Bebiana, M.D.
ALS
Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)
The specific objective of this study is to validate the practice of remote pulmonary function testing (rPFT) conducted in the home through the use of connected mobile health devices and the Penn State Hershey ALS Telemanagement…
- Trial name
- NCT03214224
- Testing
- remote pulmonary function testing, standard pulmonary function testing
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing…
- Trial name
- NCT00537446
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Amyotrophic Lateral Slerosis
Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) progressively damages the nerve cells responsible for voluntary muscle movement. Over time, this leads to weakness in different muscles such as those used for movement or breathing.
- Trial name
- IMT4LAS (NCT07413718)
- Testing
- Inspiratory muscle training
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- University Ramon Llull
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known…
- Trial name
- NCT07259980
- Testing
- Tofersen
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT01935518
- Testing
- Fasudil
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants.
- Trial name
- NCT06714396
- Testing
- QRL-101
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- QurAlis Corporation
ALS, Amyotrophic Lateral Sclerosis
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2…
- Trial name
- Pimozide2 (NCT03272503)
- Testing
- Pimozide 2mg/day (current) or 4 mg/day (study initiation)
- Where
- 9 sites in Canada
- Volunteers
- 100 people
- Sponsor
- University of Calgary
Amyotrophic Lateral Sclerosis Als
Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
The goal of the study aims to evaluate the safety and tolerability of a single intrathecal injection of RJK002 in subjects with amyotrophic lateral sclerosis (ALS), and to determine the recommended Phase II dose (RP2D).
- Trial name
- NCT06493279
- Testing
- RJK002 Intrathecal injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- RJK Biopharma Ltd
Amyotrophic Lateral Sclerosis
A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS
Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression. This study aims to investigate if ambroxol in high doses is effective in treating ALS.
- Trial name
- AMBALS (NCT05959850)
- Testing
- Ambroxol
- Where
- 5 sites in Australia
- Volunteers
- 50 people
- Sponsor
- The Florey Institute of Neuroscience and Mental Health
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis
PREVENT ALL ALS Study
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control…
- Trial name
- NCT06581861
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Amyotrophic Lateral Sclerosis
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
- Trial name
- NCT05299658
- Testing
- CNMAu8
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Clene Nanomedicine